drugset / Trial / NCT03907813

Liposomal Bupivacaine After Cesarean Delivery

NCT03907813 ↗

Phase 4 Withdrawn Wright State University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The aim of this study is to determine if local wound infiltration with liposomal bupivacaine at the time of cesarean delivery can decrease opioid use and provide adequate post-operative pain control.

Timeline

Start
2019-05-01
Primary completion
2020-06-30
Completion
2020-07-31

Outcome

Outcome not reported

Stopped: “change in design”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 20 ml Other

Indications

No indication recorded.